NASDAQ$PLRX
Pliant Therapeutics Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Pliant Therapeutics reported fourth quarter and full year 2020 financial results, and provided a corporate update.
Pliant Therapeutics reported a net loss of $19.0 million for the fourth quarter of 2020, compared to a net income of $42.2 million for the prior-year quarter, due to a decrease in related party revenue. Research and development expenses increased to $17.9 million, and general and administrative expenses were $5.6 million. The company had cash, cash equivalents, and short-term investments of $276.9 million as of December 31, 2020.
- PLN-74809 Phase 2a PET imaging trial resumed, with preliminary data expected in the first half 2021.
- PLN-74809 Phase 2a INTEGRIS trials in IPF and PSC gained momentum in the fourth quarter and are currently on track to complete enrollment by the end of 2021 and the first half of 2022, respectively.
- IND open for development of a PET tracer of the protein integrin αvβ1.
- Successful completion of PLN-1474 Phase 1 trial and transfer of PLN-1474 to Novartis.
Headline financials
Revenue & EPS history
Pliant Therapeutics · Revenue · Quarterly
$4.47M
Forward guidance
Pliant believes it has sufficient funds to meet its operating and capital requirements into 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
-1.8%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-4.2%
Avg return
30 days after
36%
9 / 25 earnings
Positive
+12.1%
Q3 2020
Best reaction
-11.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.8% | -4.2% | -4.2% | |
| Q3 2025 | +3.3% | +17.6% | -20.9% | |
| Q1 2025 | -1.5% | -2.9% | -1.4% | |
| Q4 2024 | -11.7% | +17.4% | -5.1% | |
| Q3 2024 | -4.5% | -12.0% | -6.4% | |
| Q2 2024 | -6.5% | -9.6% | -1.8% | |
| Q1 2024 | -1.4% | -1.2% | -13.4% | |
| Q4 2023 | -7.8% | -4.8% | -13.4% | |
| Q3 2023 | -8.0% | -12.4% | -2.7% | |
| Q2 2023 | +3.4% | -0.9% | -9.5% | |
| Q1 2023 | +4.2% | -0.0% | +3.0% | |
| Q4 2022 | -10.9% | -9.4% | -17.6% | |
| Q3 2022 | -6.5% | -6.7% | -14.5% | |
| Q2 2022 | +11.9% | +12.6% | +6.2% | |
| Q1 2022 | -6.8% | -1.8% | +40.5% | |
| Q4 2021 | +3.7% | -9.9% | -26.6% | |
| Q3 2021 | -4.0% | -3.2% | -17.9% | |
| Q2 2021 | -6.5% | -12.4% | -15.7% | |
| Q1 2021 | -0.1% | -14.7% | -3.1% | |
| Q4 2020 | +4.6% | +2.5% | -19.9% | |
| Q3 2019 | +12.1% | +9.9% | +21.2% | |
| Q3 2020 | +12.1% | +9.9% | +21.2% | |
| Q2 2020 | -8.5% | -8.2% | -1.2% | |
| Q4 2019 | -8.5% | -8.2% | -1.2% | |
| Q2 2019 | -8.5% | -8.2% | -1.2% | |
| Q1 2020 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro